img

Global Live and Attenuated Vaccine Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Live and Attenuated Vaccine Market Research Report 2024

According to Mr Accuracy reports’s new survey, global Live and Attenuated Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Live and Attenuated Vaccine market research.
Key manufacturers engaged in the Live and Attenuated Vaccine industry include GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc, Johnson & Johnson, CSL Limited, Emergent BioSolutions, Inc., MedImmune, LLC and Sanofi, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Live and Attenuated Vaccine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Live and Attenuated Vaccine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Live and Attenuated Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


GlaxoSmithKline
Merck & Co.
Pfizer, Inc
Astellas Pharma Inc
Johnson & Johnson
CSL Limited
Emergent BioSolutions, Inc.
MedImmune, LLC
Sanofi
Serum Institute
Segment by Type
Pediatric Vaccine
Adult Vaccines

Segment by Application


Hospitals
Clinics
Diagnostic Centers
Research Institute
Others

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Live and Attenuated Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Live and Attenuated Vaccine Market Overview
1.1 Product Overview and Scope of Live and Attenuated Vaccine
1.2 Live and Attenuated Vaccine Segment by Type
1.2.1 Global Live and Attenuated Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Pediatric Vaccine
1.2.3 Adult Vaccines
1.3 Live and Attenuated Vaccine Segment by Application
1.3.1 Global Live and Attenuated Vaccine Market Value by Application: (2024-2034)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Diagnostic Centers
1.3.5 Research Institute
1.3.6 Others
1.4 Global Live and Attenuated Vaccine Market Size Estimates and Forecasts
1.4.1 Global Live and Attenuated Vaccine Revenue 2024-2034
1.4.2 Global Live and Attenuated Vaccine Sales 2024-2034
1.4.3 Global Live and Attenuated Vaccine Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Live and Attenuated Vaccine Market Competition by Manufacturers
2.1 Global Live and Attenuated Vaccine Sales Market Share by Manufacturers (2024-2024)
2.2 Global Live and Attenuated Vaccine Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Live and Attenuated Vaccine Average Price by Manufacturers (2024-2024)
2.4 Global Live and Attenuated Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Live and Attenuated Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Live and Attenuated Vaccine, Product Type & Application
2.7 Live and Attenuated Vaccine Market Competitive Situation and Trends
2.7.1 Live and Attenuated Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Live and Attenuated Vaccine Players Market Share by Revenue
2.7.3 Global Live and Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Live and Attenuated Vaccine Retrospective Market Scenario by Region
3.1 Global Live and Attenuated Vaccine Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Live and Attenuated Vaccine Global Live and Attenuated Vaccine Sales by Region: 2024-2034
3.2.1 Global Live and Attenuated Vaccine Sales by Region: 2024-2024
3.2.2 Global Live and Attenuated Vaccine Sales by Region: 2024-2034
3.3 Global Live and Attenuated Vaccine Global Live and Attenuated Vaccine Revenue by Region: 2024-2034
3.3.1 Global Live and Attenuated Vaccine Revenue by Region: 2024-2024
3.3.2 Global Live and Attenuated Vaccine Revenue by Region: 2024-2034
3.4 North America Live and Attenuated Vaccine Market Facts & Figures by Country
3.4.1 North America Live and Attenuated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Live and Attenuated Vaccine Sales by Country (2024-2034)
3.4.3 North America Live and Attenuated Vaccine Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Live and Attenuated Vaccine Market Facts & Figures by Country
3.5.1 Europe Live and Attenuated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Live and Attenuated Vaccine Sales by Country (2024-2034)
3.5.3 Europe Live and Attenuated Vaccine Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Live and Attenuated Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Live and Attenuated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Live and Attenuated Vaccine Sales by Country (2024-2034)
3.6.3 Asia Pacific Live and Attenuated Vaccine Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Live and Attenuated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Live and Attenuated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Live and Attenuated Vaccine Sales by Country (2024-2034)
3.7.3 Latin America Live and Attenuated Vaccine Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Live and Attenuated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Live and Attenuated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Live and Attenuated Vaccine Sales by Country (2024-2034)
3.8.3 Middle East and Africa Live and Attenuated Vaccine Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Live and Attenuated Vaccine Sales by Type (2024-2034)
4.1.1 Global Live and Attenuated Vaccine Sales by Type (2024-2024)
4.1.2 Global Live and Attenuated Vaccine Sales by Type (2024-2034)
4.1.3 Global Live and Attenuated Vaccine Sales Market Share by Type (2024-2034)
4.2 Global Live and Attenuated Vaccine Revenue by Type (2024-2034)
4.2.1 Global Live and Attenuated Vaccine Revenue by Type (2024-2024)
4.2.2 Global Live and Attenuated Vaccine Revenue by Type (2024-2034)
4.2.3 Global Live and Attenuated Vaccine Revenue Market Share by Type (2024-2034)
4.3 Global Live and Attenuated Vaccine Price by Type (2024-2034)
5 Segment by Application
5.1 Global Live and Attenuated Vaccine Sales by Application (2024-2034)
5.1.1 Global Live and Attenuated Vaccine Sales by Application (2024-2024)
5.1.2 Global Live and Attenuated Vaccine Sales by Application (2024-2034)
5.1.3 Global Live and Attenuated Vaccine Sales Market Share by Application (2024-2034)
5.2 Global Live and Attenuated Vaccine Revenue by Application (2024-2034)
5.2.1 Global Live and Attenuated Vaccine Revenue by Application (2024-2024)
5.2.2 Global Live and Attenuated Vaccine Revenue by Application (2024-2034)
5.2.3 Global Live and Attenuated Vaccine Revenue Market Share by Application (2024-2034)
5.3 Global Live and Attenuated Vaccine Price by Application (2024-2034)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.1.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Merck & Co.
6.2.1 Merck & Co. Corporation Information
6.2.2 Merck & Co. Description and Business Overview
6.2.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
6.2.5 Merck & Co. Recent Developments/Updates
6.3 Pfizer, Inc
6.3.1 Pfizer, Inc Corporation Information
6.3.2 Pfizer, Inc Description and Business Overview
6.3.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
6.3.5 Pfizer, Inc Recent Developments/Updates
6.4 Astellas Pharma Inc
6.4.1 Astellas Pharma Inc Corporation Information
6.4.2 Astellas Pharma Inc Description and Business Overview
6.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
6.4.5 Astellas Pharma Inc Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 CSL Limited
6.6.1 CSL Limited Corporation Information
6.6.2 CSL Limited Description and Business Overview
6.6.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.6.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
6.6.5 CSL Limited Recent Developments/Updates
6.7 Emergent BioSolutions, Inc.
6.6.1 Emergent BioSolutions, Inc. Corporation Information
6.6.2 Emergent BioSolutions, Inc. Description and Business Overview
6.6.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
6.7.5 Emergent BioSolutions, Inc. Recent Developments/Updates
6.8 MedImmune, LLC
6.8.1 MedImmune, LLC Corporation Information
6.8.2 MedImmune, LLC Description and Business Overview
6.8.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.8.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
6.8.5 MedImmune, LLC Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Sanofi Live and Attenuated Vaccine Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Serum Institute
6.10.1 Serum Institute Corporation Information
6.10.2 Serum Institute Description and Business Overview
6.10.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
6.10.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Live and Attenuated Vaccine Industry Chain Analysis
7.2 Live and Attenuated Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Live and Attenuated Vaccine Production Mode & Process
7.4 Live and Attenuated Vaccine Sales and Marketing
7.4.1 Live and Attenuated Vaccine Sales Channels
7.4.2 Live and Attenuated Vaccine Distributors
7.5 Live and Attenuated Vaccine Customers
8 Live and Attenuated Vaccine Market Dynamics
8.1 Live and Attenuated Vaccine Industry Trends
8.2 Live and Attenuated Vaccine Market Drivers
8.3 Live and Attenuated Vaccine Market Challenges
8.4 Live and Attenuated Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Live and Attenuated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Live and Attenuated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Live and Attenuated Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Live and Attenuated Vaccine Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Live and Attenuated Vaccine Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Live and Attenuated Vaccine Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Live and Attenuated Vaccine Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Live and Attenuated Vaccine Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Live and Attenuated Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Live and Attenuated Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Live and Attenuated Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Live and Attenuated Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Live and Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live and Attenuated Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Live and Attenuated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Live and Attenuated Vaccine Sales by Region (2024-2024) & (K Units)
Table 18. Global Live and Attenuated Vaccine Sales Market Share by Region (2024-2024)
Table 19. Global Live and Attenuated Vaccine Sales by Region (2024-2034) & (K Units)
Table 20. Global Live and Attenuated Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Live and Attenuated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Live and Attenuated Vaccine Revenue Market Share by Region (2024-2024)
Table 23. Global Live and Attenuated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Live and Attenuated Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Live and Attenuated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Live and Attenuated Vaccine Sales by Country (2024-2024) & (K Units)
Table 27. North America Live and Attenuated Vaccine Sales by Country (2024-2034) & (K Units)
Table 28. North America Live and Attenuated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Live and Attenuated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Live and Attenuated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Live and Attenuated Vaccine Sales by Country (2024-2024) & (K Units)
Table 32. Europe Live and Attenuated Vaccine Sales by Country (2024-2034) & (K Units)
Table 33. Europe Live and Attenuated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Live and Attenuated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Live and Attenuated Vaccine Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Live and Attenuated Vaccine Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Live and Attenuated Vaccine Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Live and Attenuated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Live and Attenuated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Live and Attenuated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Live and Attenuated Vaccine Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Live and Attenuated Vaccine Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Live and Attenuated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Live and Attenuated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Live and Attenuated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Live and Attenuated Vaccine Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Live and Attenuated Vaccine Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Live and Attenuated Vaccine Sales (K Units) by Type (2024-2024)
Table 51. Global Live and Attenuated Vaccine Sales (K Units) by Type (2024-2034)
Table 52. Global Live and Attenuated Vaccine Sales Market Share by Type (2024-2024)
Table 53. Global Live and Attenuated Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Live and Attenuated Vaccine Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Live and Attenuated Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Live and Attenuated Vaccine Revenue Market Share by Type (2024-2024)
Table 57. Global Live and Attenuated Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Live and Attenuated Vaccine Price (US$/Unit) by Type (2024-2024)
Table 59. Global Live and Attenuated Vaccine Price (US$/Unit) by Type (2024-2034)
Table 60. Global Live and Attenuated Vaccine Sales (K Units) by Application (2024-2024)
Table 61. Global Live and Attenuated Vaccine Sales (K Units) by Application (2024-2034)
Table 62. Global Live and Attenuated Vaccine Sales Market Share by Application (2024-2024)
Table 63. Global Live and Attenuated Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Live and Attenuated Vaccine Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Live and Attenuated Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Live and Attenuated Vaccine Revenue Market Share by Application (2024-2024)
Table 67. Global Live and Attenuated Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Live and Attenuated Vaccine Price (US$/Unit) by Application (2024-2024)
Table 69. Global Live and Attenuated Vaccine Price (US$/Unit) by Application (2024-2034)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. GlaxoSmithKline Live and Attenuated Vaccine Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Merck & Co. Corporation Information
Table 76. Merck & Co. Description and Business Overview
Table 77. Merck & Co. Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Merck & Co. Live and Attenuated Vaccine Product
Table 79. Merck & Co. Recent Developments/Updates
Table 80. Pfizer, Inc Corporation Information
Table 81. Pfizer, Inc Description and Business Overview
Table 82. Pfizer, Inc Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Pfizer, Inc Live and Attenuated Vaccine Product
Table 84. Pfizer, Inc Recent Developments/Updates
Table 85. Astellas Pharma Inc Corporation Information
Table 86. Astellas Pharma Inc Description and Business Overview
Table 87. Astellas Pharma Inc Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Astellas Pharma Inc Live and Attenuated Vaccine Product
Table 89. Astellas Pharma Inc Recent Developments/Updates
Table 90. Johnson & Johnson Corporation Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Johnson & Johnson Live and Attenuated Vaccine Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. CSL Limited Corporation Information
Table 96. CSL Limited Description and Business Overview
Table 97. CSL Limited Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. CSL Limited Live and Attenuated Vaccine Product
Table 99. CSL Limited Recent Developments/Updates
Table 100. Emergent BioSolutions, Inc. Corporation Information
Table 101. Emergent BioSolutions, Inc. Description and Business Overview
Table 102. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product
Table 104. Emergent BioSolutions, Inc. Recent Developments/Updates
Table 105. MedImmune, LLC Corporation Information
Table 106. MedImmune, LLC Description and Business Overview
Table 107. MedImmune, LLC Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. MedImmune, LLC Live and Attenuated Vaccine Product
Table 109. MedImmune, LLC Recent Developments/Updates
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Sanofi Live and Attenuated Vaccine Product
Table 114. Sanofi Recent Developments/Updates
Table 115. Serum Institute Corporation Information
Table 116. Serum Institute Description and Business Overview
Table 117. Serum Institute Live and Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Serum Institute Live and Attenuated Vaccine Product
Table 119. Serum Institute Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Live and Attenuated Vaccine Distributors List
Table 123. Live and Attenuated Vaccine Customers List
Table 124. Live and Attenuated Vaccine Market Trends
Table 125. Live and Attenuated Vaccine Market Drivers
Table 126. Live and Attenuated Vaccine Market Challenges
Table 127. Live and Attenuated Vaccine Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Live and Attenuated Vaccine
Figure 2. Global Live and Attenuated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Live and Attenuated Vaccine Market Share by Type in 2022 & 2034
Figure 4. Pediatric Vaccine Product Picture
Figure 5. Adult Vaccines Product Picture
Figure 6. Global Live and Attenuated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Live and Attenuated Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Diagnostic Centers
Figure 11. Research Institute
Figure 12. Others
Figure 13. Global Live and Attenuated Vaccine Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global Live and Attenuated Vaccine Market Size (2024-2034) & (US$ Million)
Figure 15. Global Live and Attenuated Vaccine Sales (2024-2034) & (K Units)
Figure 16. Global Live and Attenuated Vaccine Average Price (US$/Unit) & (2024-2034)
Figure 17. Live and Attenuated Vaccine Report Years Considered
Figure 18. Live and Attenuated Vaccine Sales Share by Manufacturers in 2022
Figure 19. Global Live and Attenuated Vaccine Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Live and Attenuated Vaccine Players: Market Share by Revenue in 2022
Figure 21. Live and Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 22. Global Live and Attenuated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 23. North America Live and Attenuated Vaccine Sales Market Share by Country (2024-2034)
Figure 24. North America Live and Attenuated Vaccine Revenue Market Share by Country (2024-2034)
Figure 25. United States Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Canada Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. Europe Live and Attenuated Vaccine Sales Market Share by Country (2024-2034)
Figure 28. Europe Live and Attenuated Vaccine Revenue Market Share by Country (2024-2034)
Figure 29. Germany Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. France Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. U.K. Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Italy Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Russia Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Asia Pacific Live and Attenuated Vaccine Sales Market Share by Region (2024-2034)
Figure 35. Asia Pacific Live and Attenuated Vaccine Revenue Market Share by Region (2024-2034)
Figure 36. China Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Japan Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. South Korea Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. India Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Australia Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. China Taiwan Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Southeast Asia Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Latin America Live and Attenuated Vaccine Sales Market Share by Country (2024-2034)
Figure 44. Latin America Live and Attenuated Vaccine Revenue Market Share by Country (2024-2034)
Figure 45. Mexico Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Brazil Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Argentina Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Country (2024-2034)
Figure 49. Middle East & Africa Live and Attenuated Vaccine Revenue Market Share by Country (2024-2034)
Figure 50. Turkey Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Saudi Arabia Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. UAE Live and Attenuated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Global Sales Market Share of Live and Attenuated Vaccine by Type (2024-2034)
Figure 54. Global Revenue Market Share of Live and Attenuated Vaccine by Type (2024-2034)
Figure 55. Global Live and Attenuated Vaccine Price (US$/Unit) by Type (2024-2034)
Figure 56. Global Sales Market Share of Live and Attenuated Vaccine by Application (2024-2034)
Figure 57. Global Revenue Market Share of Live and Attenuated Vaccine by Application (2024-2034)
Figure 58. Global Live and Attenuated Vaccine Price (US$/Unit) by Application (2024-2034)
Figure 59. Live and Attenuated Vaccine Value Chain
Figure 60. Live and Attenuated Vaccine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed